Veradermics
Biologics & Biosimilars · Dermatology
$268.8Mtotal raised · 6 rounds on record
$30Mlatest round · Convertible Note · May 2026 · 6 mo ago
2backers · Longitude Capital, SR One
2020founded
Funding and backers
Total raised
$268.8M
6 rounds on record
Latest round
$30M
Convertible Note · May 2026 · 6 mo ago
Backers
2
Longitude Capital, SR One
The money's age
Fresh money
6 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 1
Raised a round Convertible Note $30M · SEC Form D
Oct 14, 2025
Raised a round Venture round $135M · SEC Form D
Nov 25, 2024
Raised a round Venture round $66.6M · SEC Form D
Apr 25, 2023
Raised a round Venture round $15M · SEC Form D
Sep 22, 2021
Raised a round Venture round $22.2M · SEC Form D
Sep 29, 2020
Took on debt financing $476k · SEC Form D
2020
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Convertible Note | May 2026 | $30M | — | SEC Form D |
| Venture round | Oct 2025 | $135M | — | SEC Form D |
| Venture round | Nov 2024 | $66.6M | — | SEC Form D |
| Venture round | Apr 2023 | $15M | — | SEC Form D |
| Venture round | Sep 2021 | $22.2M | — | SEC Form D |
| Debt Financing | Sep 2020 | $476k | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | VeraDermics, Inc | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Timothy DursoExecutive Officer, DirectorSEC Form D
Reid WaldmanExecutive Officer, DirectorSEC Form D
Michael GrecoExecutive OfficerSEC Form D
Mark NeumannExecutive OfficerSEC Form D
Dominic CarranoExecutive OfficerSEC Form D
Tim DursoExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
EnteroBiotix is a clinical-stage biopharmaceutical company developing best-in-class full-spectrum microbial therapeutics.
AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming HBV treatment for cure and advancing…
Opna Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics. The…
Neurogastrx, Inc.. Thank you for visiting the website for Neurogastrx, Inc. ("Company"), a privately held, late clinical-stage…
Stelexis BioSciences is a clinical-stage biopharmaceutical company created to accelerate novel treatments that aim to eradicate…
Nuance Pharma are an innovation focused biopharmaceutical company, with both late-stage clinical pipeline and commercial stage asset…
Financials
Total raised
$269.3M
Latest round
Convertible Note
Funding rounds
6
People
Timothy Durso
Executive Officer, Director
Reid Waldman
Executive Officer, Director
Michael Greco
Executive Officer
Mark Neumann
Executive Officer
Dominic Carrano
Executive Officer
Tim Durso
Executive Officer
Vladimir Coric
Director
Jane Grant-Kels
Director
John Childs
Director
Amanda Birdsey-Benson
Director
Christopher Eklund
Director
Patrick Enright
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
SR OneVia a fund
Longitude CapitalVia a fund
78 portfolio companies: Zenas BioPharma, Mobia Medical, Inc. and 76 more
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Veradermics to Present at Upcoming September Investor Conferences
NEW HAVEN, Conn., September 03, 2026--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that company management will p
Read more
Report
Veradermics to Present at Upcoming September Investor Conferences - Company Announcement - FT.com
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report
Veradermics: $820 Million Cash Runway Extends Into 2030 As Hair-Loss Drug Approaches Phase 3 Readouts
Veradermics ended the second quarter with approximately $819.9 million in cash, cash equivalents and marketable securities, providing a runway expected to extend into 2030 as its lead hair-loss program moves through multiple late-stage clinical milestones
Read more
Report
Veradermics' Oral VDPHL01 Delivers Positive Study '207' Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study '306' Readout
Read more
Report
Veradermics soars on positive data for baldness treatment
The results could support the first approval in decades for an oral medicine that can treat male pattern baldness, though the therapy will face competition from generics and over-the-counter medications.
Read more
Report
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 '302' Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
Read more
Report
Baldness Biotech Veradermics Prices $256M IPO for Pivotal Tests of Pill for Hair Loss
Veradermics's drug, a pill version of the topical hair loss product minoxidil, was developed with technology intended to avoid the cardiovascular risks associated with oral dosing of this compound. The first of three pivotal clinical trials is expected to
Read more
Report
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
San Antonio
United States
HQ
New Haven
United States
Sales office
Dr. Waldman is the Chief Executive Officer (CEO) of Veradermics. Under his stewardship, he has positioned Veradermics fo
470 James St., Suite 2A, New Haven, CT 06513